{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:00:19Z","timestamp":1787241619334,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metformin is a hypoglycaemic medication that has been proposed to treat or prevent preeclampsia. Combining national birth data from Scotland and Sweden, we investigated whether metformin used during pregnancy was associated with an altered risk of developing a hypertensive disorder of pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilised data from two population-based cohorts: Scotland (2012\u20132018) and Sweden (2007\u20132019). Nulliparous women with gestational diabetes or type 2 diabetes who had birth outcome data linked with medications prescribed during pregnancy were included. The association between metformin prescription and hypertensive disorders of pregnancy was characterised using inverse probability weighted regression analysis, adjusting for variables that predict metformin use and potential confounders. Adverse neonatal outcomes were included as secondary outcomes. Results from both countries were then combined in a meta-analysis using a random effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Scottish cohort included 3859 women with gestational diabetes or type 2 diabetes. Of these women, 30.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091187) received at least one metformin prescription during pregnancy. For Sweden, 7771 women with gestational diabetes were included where 19.3% (1498) used metformin during pregnancy. Metformin prescription was not associated with an altered risk of any hypertensive disorder of pregnancy (Scotland adjusted relative risk (aRR) 0.88 [95% confidence interval (CI) 0.66\u20131.19]; Sweden aRR 1.08 [95% CI 0.86\u20131.37]) or preeclampsia (Scotland aRR 1.02 [95% CI 0.66\u20131.60]; Sweden aRR 1.00 [95% CI 0.72\u20131.39]). Combining adjusted results in a meta-analysis produced similar findings, with a pooled RR of 0.98 (95% CI 0.79\u20131.18) for any hypertensive disorder and RR 1.01 ([95% CI 0.73\u20131.28]) for preeclampsia. For neonatal outcomes, metformin was associated with a reduced risk of birthweight\u2009&gt;\u20094500\u00a0g in Scotland (aRR 0.39 [95% CI 0.21\u20130.71]) but not in Sweden. There was no association between metformin and preterm birth or birthweight\u2009&lt;\u20093rd or\u2009&lt;\u200910th percentiles. Pooling results from both countries, metformin was not associated with adverse neonatal outcomes, including preterm birth (RR 1.00 [95% CI 0.89\u20131.13]), and birthweight\u2009&lt;\u200910th percentile (RR 0.82 [95% CI 0.60\u20131.13]) or\u2009&lt;\u20093rd percentile (RR 0.78 [95% CI 0.41\u20131.48]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this two-country analysis, metformin use in pregnancy among women with diabetes was not associated with an altered risk of developing any hypertensive disorder of pregnancy. In the combined meta-analysis, metformin was not associated with an altered risk of adverse neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03628-0","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:01:58Z","timestamp":1727449318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metformin use and preeclampsia risk in women with diabetes: a two-country cohort analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Hannah","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manarangi","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cluver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Mehdipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hiscock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Doust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hesselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"3628_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","volume":"170","author":"E Abalos","year":"2013","unstructured":"Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170:1\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3628_CR2","doi-asserted-by":"crossref","unstructured":"Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659.","DOI":"10.1002\/14651858.CD004659.pub3"},{"key":"3628_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/uog.18816","volume":"50","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LCY, Syngelaki A, O\u2019Gorman N, de Paco MC, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50:492\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"3628_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/1471-0528.17370","volume":"130","author":"P von Dadelszen","year":"2023","unstructured":"von Dadelszen P, Syngelaki A, Akolekar R, Magee LA, Nicolaides KH. Preterm and term pre-eclampsia: Relative burdens of maternal and perinatal complications. BJOG. 2023;130:524\u201330.","journal-title":"BJOG"},{"key":"3628_CR5","doi-asserted-by":"publisher","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.12.019","volume":"214","author":"FC Brownfoot","year":"2016","unstructured":"Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. AJOG. 2016;214:356.e1-356.e15.","journal-title":"AJOG"},{"key":"3628_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082880","volume":"14","author":"CA Cluver","year":"2024","unstructured":"Cluver CA, Bergman L, Imberg H, Mol BW, Hall D, Bekker A, et al. Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial. BMJ Open. 2024;14: e082880.","journal-title":"BMJ Open"},{"key":"3628_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2103","volume":"374","author":"CA Cluver","year":"2021","unstructured":"Cluver CA, Hiscock R, Decloedt EH, Hall DR, Schell S, Mol BW, et al. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021;374: n2103.","journal-title":"BMJ"},{"key":"3628_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/dme.13523","volume":"35","author":"A Alqudah","year":"2018","unstructured":"Alqudah A, Mckinley MC, Mcnally R, Graham U, Watson CJ, Lyons TJ, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018;35:160\u201372.","journal-title":"Diabet Med"},{"key":"3628_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1464-5491.2011.03361.x","volume":"28","author":"JEL Goh","year":"2011","unstructured":"Goh JEL, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011;28:1082\u20137.","journal-title":"Diabet Med"},{"key":"3628_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1046\/j.1464-5491.2000.00314.x","volume":"17","author":"E Hellmuth","year":"2000","unstructured":"Hellmuth E, Damm P, M\u00f8lsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17:507\u201311.","journal-title":"Diabet Med"},{"key":"3628_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejogrb.2011.03.024","volume":"157","author":"V De Leo","year":"2011","unstructured":"De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011;157:63\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3628_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/jdi.12552","volume":"8","author":"A Collier","year":"2017","unstructured":"Collier A, Abraham EC, Armstrong J, Godwin J, Monteath K, Lindsay R. Reported prevalence of gestational diabetes in Scotland: The relationship with obesity, age, socioeconomic status, smoking and macrosomia, and how many are we missing? J Diabetes Invest. 2017;8:161\u20137.","journal-title":"J Diabetes Invest"},{"key":"3628_CR13","unstructured":"NSS Information and Intelligence. Assessment of SMR02 (Maternity Inpatient and Day Case) Data; Scotland 2017\u20132018. Scotland; 2019. Available from: https:\/\/www.scotpho.org.uk\/media\/2411\/20191023-assessment-of-smr02-data-scotland-2017-2018.pdf."},{"key":"3628_CR14","first-page":"2021","volume":"31","author":"Public Health Scotland","year":"2022","unstructured":"Public Health Scotland. Births in Scotland: Year ending. March 2022;31:2021.","journal-title":"Births in Scotland: Year ending"},{"key":"3628_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10654-022-00947-5","volume":"38","author":"S Cnattingius","year":"2023","unstructured":"Cnattingius S, K\u00e4ll\u00e9n K, Sandstr\u00f6m A, Rydberg H, M\u00e5nsson H, Stephansson O, et al. The Swedish medical birth register during five decades: documentation of the content and quality of the register. Eur J Epidemiol. 2023;38:109\u201320.","journal-title":"Eur J Epidemiol"},{"key":"3628_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2014Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3628_CR17","unstructured":"K\u00e4ll\u00e9n B, K\u00e4ll\u00e9n K. The Swedish Medical Birth Register - a summary of content and quality. Socialstyrelsen; 2003. Article no: 2003-112-3. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2003-112-3_20031123.pdf."},{"key":"3628_CR18","unstructured":"Socialstyrelsen. National Patient Register. Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/ (2023)."},{"key":"3628_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1471-2393-14-185","volume":"14","author":"M Lindqvist","year":"2014","unstructured":"Lindqvist M, Persson M, Lindkvist M, Mogren I. No consensus on gestational diabetes mellitus screening regimes in Sweden: pregnancy outcomes in relation to different screening regimes 2011 to 2012, a cross-sectional study. BMC Pregnancy Childbirth. 2014;14:185.","journal-title":"BMC Pregnancy Childbirth"},{"key":"3628_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-3016.2007.00836.x","volume":"21","author":"Z-C Luo","year":"2007","unstructured":"Luo Z-C, An N, Xu H-R, Larante A, Audibert F, Fraser WD. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol. 2007;21:36\u201345.","journal-title":"Paediatr Perinat Epidemiol"},{"key":"3628_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)60932-6","volume":"384","author":"J Villar","year":"2014","unstructured":"Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet. 2014;384:857\u201368.","journal-title":"Lancet"},{"key":"3628_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000515893","volume":"86","author":"X Wang","year":"2021","unstructured":"Wang X, Liu W, Chen H, Chen Q. Comparison of Insulin, Metformin, and Glyburide on Perinatal Complications of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. Gynecol Obstet Invest. 2021;86:218\u201330.","journal-title":"Gynecol Obstet Invest"},{"key":"3628_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/humrep\/deh347","volume":"19","author":"E Vanky","year":"2004","unstructured":"Vanky E. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19:1734\u201340.","journal-title":"Hum Reprod"},{"key":"3628_CR24","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/humrep\/17.11.2858","volume":"17","author":"CJ Glueck","year":"2002","unstructured":"Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17:2858\u201364.","journal-title":"Hum Reprod"},{"key":"3628_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.14310\/horm.2002.1266","volume":"9","author":"M Jinno","year":"2010","unstructured":"Jinno M, Kondou K, Teruya K. Low-dose metformin improves pregnancy rate in in vitro fertilization repeaters without polycystic ovary syndrome: Prediction of effectiveness by multiple parameters related to insulin resistance. Hormones (Athens). 2010;9:161\u201370.","journal-title":"Hormones (Athens)"},{"key":"3628_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33\u20138.","journal-title":"Am Stat"},{"key":"3628_CR27","unstructured":"StataCorp. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC;\u00a02023."},{"key":"3628_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1509819","volume":"374","author":"A Syngelaki","year":"2016","unstructured":"Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016;374:434\u201343.","journal-title":"N Engl J Med."},{"key":"3628_CR29","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3390\/ijerph191710846","volume":"19","author":"N Malaza","year":"2022","unstructured":"Malaza N, Masete M, Adam S, Dias S, Nyawo T, Pheiffer C. A Systematic Review to Compare Adverse Pregnancy Outcomes in Women with Pregestational Diabetes and Gestational Diabetes. Int J Environ Res Public Health. 2022;19:10846.","journal-title":"Int J Environ Res Public Health"},{"key":"3628_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(20)30310-7","volume":"8","author":"DS Feig","year":"2020","unstructured":"Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8:834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3628_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2213-8587(23)00004-9","volume":"11","author":"DS Feig","year":"2023","unstructured":"Feig DS, Sanchez JJ, Murphy KE, Asztalos E, Zinman B, Simmons D, et al. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol. 2023;11:191\u2013202.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3628_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002848","volume":"16","author":"JL Tarry-Adkins","year":"2019","unstructured":"Tarry-Adkins JL, Aiken CE, Ozanne SE. Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Med. 2019;16: e1002848.","journal-title":"PLoS Med"},{"key":"3628_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jamapediatrics.2018.4214","volume":"173","author":"SN Landi","year":"2019","unstructured":"Landi SN, Radke S, Engel SM, Boggess K, St\u00fcrmer T, Howe AS, et al. Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatr. 2019;173:160.","journal-title":"JAMA Pediatr"},{"key":"3628_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/OGX.0b013e3182331028","volume":"66","author":"D Raymond","year":"2011","unstructured":"Raymond D, Peterson E. A Critical Review of Early-Onset and Late-Onset Preeclampsia. Obstet Gynecol Surv. 2011;66:497.","journal-title":"Obstet Gynecol Surv"},{"key":"3628_CR35","unstructured":"Scottish Intercollegiate Guidelines Network. Management of diabetes: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010. Available from: https:\/\/www.sign.ac.uk\/media\/2205\/sign-171-management-of-diabetes-in-pregnancy.pdf."},{"key":"3628_CR36","unstructured":"National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period [NICE Guideline No. 3]. 2020. Available from: https:\/\/www.nice.org.uk\/guidance\/ng3\/resources\/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-pdf-51038446021."},{"key":"3628_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11892-015-0579-4","volume":"15","author":"TL Weissgerber","year":"2015","unstructured":"Weissgerber TL, Mudd LM. Preeclampsia and Diabetes. Curr Diab Rep. 2015;15:9.","journal-title":"Curr Diab Rep"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03628-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:05:55Z","timestamp":1727449555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03628-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3628"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03628-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted through the Mercy Health Ethics Committee [HREC 2019\u2013005] on 12th November 2019 and the Swedish Ethical Review Authority [2019\u201304-25] on 28th January 2020. Patient data was deidentified, and accordingly, a waiver of individual participant consent was approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}